NVCN.TO
Neovasc Inc. [NVCN.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVCN.TO Stock Summary
In the News
NVCN.TO Financial details
Company Rating
Neutral
Market Cap
110.78M
Income
-47.35M
Revenue
3.81M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-1.73
Forward P/E
-
PEG
-0.71
P/S
21.78
P/B
5.17
P/C
-
P/FCF
-3.32
Quick Ratio
2.81
Current Ratio
2.96
Debt / Equity
0.82
LT Debt / Equity
0.81
-
-
EPS (TTM)
-12.29
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
16.82%
Revenue Q/Q
57.36%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-122%
ROE
-154%
ROC
-1.18%
Gross Margin
80%
Oper. Margin
-887%
Profit Margin
-1244%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.0-41.2
52W High
-
52W Low
-
RSI
-
Rel Volume
0.05
Avg Volume
891
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.0138
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
NVCN.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.24 | 8.03 | 2.94 | 1.01 | 0 | |
| Net income per share | -76.3 | -134.88 | -43.04 | -9.88 | 0 | |
| Operating cash flow per share | -16.1 | -92.04 | -44.16 | -10.76 | 0 | |
| Free cash flow per share | -16.23 | -92.97 | -44.67 | -10.83 | 0 | |
| Cash per share | 6.53 | 20.32 | 19.4 | 20.46 | 0 | |
| Book value per share | -6.83 | -55.46 | 2.97 | 20.73 | 0 | |
| Tangible book value per share | -6.83 | -55.46 | 2.97 | 20.73 | 0 | |
| Share holders equity per share | -6.83 | -55.46 | 2.97 | 20.73 | 0 | |
| Interest debt per share | 9.32 | 60.29 | 14.54 | 3.81 | 0 | |
| Market cap | 8.61M | 1.41M | 643.91K | 1.15M | 0 | |
| Enterprise value | 13.99M | 11.69M | -3.63M | -41.43M | -12.8M | |
| P/E ratio | -0.08 | -0.04 | -0.02 | -0.05 | 0 | |
| Price to sales ratio | 4.92 | 0.68 | 0.33 | 0.45 | 0 | |
| POCF ratio | -0.38 | -0.06 | -0.02 | -0.04 | 0 | |
| PFCF ratio | -0.37 | -0.06 | -0.02 | -0.04 | 0 | |
| P/B Ratio | -0.89 | -0.1 | 0.33 | 0.02 | 0 | |
| PTB ratio | -0.89 | -0.1 | 0.33 | 0.02 | 0 | |
| EV to sales | 8 | 5.59 | -1.86 | -16.26 | -3.36 | |
| Enterprise value over EBITDA | -0.13 | -0.4 | 0.1 | 1.05 | 0.35 | |
| EV to operating cash flow | -0.61 | -0.49 | 0.12 | 1.53 | 0.51 | |
| EV to free cash flow | -0.61 | -0.48 | 0.12 | 1.52 | 0.51 | |
| Earnings yield | -12.55 | -24.86 | -44.56 | -21.71 | 0 | |
| Free cash flow yield | -2.67 | -17.14 | -46.25 | -23.79 | 0 | |
| Debt to equity | -1.36 | -1.08 | 4.38 | 0.17 | 0.82 | |
| Debt to assets | 1.1 | 1.54 | 0.48 | 0.14 | 0.34 | |
| Net debt to EBITDA | -0.05 | -0.35 | 0.12 | 1.07 | 0.35 | |
| Current ratio | 1.3 | 0.54 | 2.05 | 11.08 | 2.96 | |
| Interest coverage | 0 | -224.97 | -33.67 | -49.29 | -22.23 | |
| Income quality | 0.21 | 0.68 | 1.03 | 1.09 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 7.35 | 4.32 | 6.75 | 5.75 | 4.11 | |
| Research and developement to revenue | 9.18 | 9.57 | 10.42 | 6.06 | 4.61 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to revenue | -0.11 | -0.12 | -0.17 | -0.06 | -0.01 | |
| Capex to depreciation | -0.5 | -0.38 | -0.44 | -0.24 | -0.16 | |
| Stock based compensation to revenue | 1.88 | 1.52 | 2.51 | 2.07 | 2.08 | |
| Graham number | 108.26 | 410.26 | 53.59 | 67.89 | 0 | |
| ROIC | -8.85 | -14.76 | -2.96 | -0.51 | -1.16 | |
| Return on tangible assets | -9.01 | -3.48 | -1.61 | -0.38 | -1.06 | |
| Graham Net | -8.22 | -70.44 | -2.6 | 15.62 | 0 | |
| Working capital | 2.46M | -6.71M | 8.07M | 50.24M | 19.72M | |
| Tangible asset value | -9.67M | -14.45M | 1.98M | 52.23M | 15.84M | |
| Net current asset value | -10.92M | -16.54M | -169.62K | 41.22M | 6.89M | |
| Invested capital | -1.36 | -1.08 | 4.38 | 0.17 | 0.82 | |
| Average receivables | 1.19M | 836.53K | 942.68K | 1.25M | 1.96M | |
| Average payables | 1.08M | 2.45M | 3.85M | 2.57M | 1.81M | |
| Average inventory | 328.65K | 438.7K | 729.06K | 1.16M | 1.28M | |
| Days sales outstanding | 181.67 | 140.01 | 201.94 | 202.46 | 240.19 | |
| Days payables outstanding | 895.62 | 3.18K | 3.03K | 942.13 | 1.03K | |
| Days of inventory on hand | 257.85 | 492.56 | 686.64 | 972.16 | 512.26 | |
| Receivables turnover | 2.01 | 2.61 | 1.81 | 1.8 | 1.52 | |
| Payables turnover | 0.41 | 0.11 | 0.12 | 0.39 | 0.35 | |
| Inventory turnover | 1.42 | 0.74 | 0.53 | 0.38 | 0.71 | |
| ROE | 11.18 | 2.43 | -14.51 | -0.48 | -2.6 | |
| Capex per share | -0.13 | -0.93 | -0.51 | -0.07 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.23 | 0.3 | 0.34 | 0 | |
| Net income per share | -0.09 | -5.12 | -3.58 | -3.59 | 0 | |
| Operating cash flow per share | -0.06 | -2.58 | -2.29 | -2.29 | 0 | |
| Free cash flow per share | -0.07 | -2.58 | -2.31 | -2.3 | 0 | |
| Cash per share | 0.76 | 16.29 | 13.78 | 11.39 | 0 | |
| Book value per share | 0.77 | 16.15 | 13.02 | 10.22 | 0 | |
| Tangible book value per share | 0.77 | 16.15 | 13.02 | 10.22 | 0 | |
| Share holders equity per share | 0.77 | 16.15 | 13.02 | 10.22 | 0 | |
| Interest debt per share | 0.14 | 4.74 | 4.64 | 4.79 | 0 | |
| Market cap | 30.76M | 1.19M | 16.76M | 17.74M | 0 | |
| Enterprise value | -11.82M | -30.48M | -8.58M | -794.06K | -12.8M | |
| P/E ratio | -1.25 | -0.02 | -0.43 | -0.45 | 0 | |
| Price to sales ratio | 40.52 | 1.95 | 20.49 | 19.22 | 0 | |
| POCF ratio | -7.01 | -0.17 | -2.68 | -2.82 | 0 | |
| PFCF ratio | -6.98 | -0.17 | -2.66 | -2.82 | 0 | |
| P/B Ratio | 0.59 | 0.03 | 0.47 | 0.63 | 0 | |
| PTB ratio | 0.59 | 0.03 | 0.47 | 0.63 | 0 | |
| EV to sales | -15.57 | -49.91 | -10.49 | -0.86 | -8.81 | |
| Enterprise value over EBITDA | 2.1 | 4.05 | 0.95 | 0.11 | 0.98 | |
| EV to operating cash flow | 2.69 | 4.37 | 1.37 | 0.13 | 2.37 | |
| EV to free cash flow | 2.68 | 4.37 | 1.36 | 0.13 | 2.37 | |
| Earnings yield | -0.2 | -11.65 | -0.58 | -0.56 | 0 | |
| Free cash flow yield | -0.14 | -5.86 | -0.38 | -0.36 | 0 | |
| Debt to equity | 0.17 | 0.29 | 0.35 | 0.45 | 0.82 | |
| Debt to assets | 0.14 | 0.21 | 0.24 | 0.29 | 0.34 | |
| Net debt to EBITDA | 7.57 | 4.21 | 2.8 | 2.5 | 0.98 | |
| Current ratio | 11.08 | 12.88 | 9.66 | 8.44 | 2.96 | |
| Interest coverage | -20.68 | -18.41 | -21.02 | -15.43 | -35.62 | |
| Income quality | 0.71 | 0.69 | 0.7 | 0.77 | 0.39 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.53 | 4.54 | 4.24 | 2.69 | 4.64 | |
| Research and developement to revenue | 4.75 | 5.35 | 5.31 | 4.38 | 4.05 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.02 | 0 | -0.06 | 0 | 0 | |
| Capex to depreciation | -0.12 | 0 | -0.48 | -0.05 | 0 | |
| Stock based compensation to revenue | -1.25 | 1.73 | 0.73 | 1 | 3.67 | |
| Graham number | 1.26 | 43.13 | 32.37 | 28.75 | 0 | |
| ROIC | -0.1 | -0.16 | -0.18 | -0.19 | -0.43 | |
| Return on tangible assets | -0.09 | -0.23 | -0.19 | -0.22 | -0.36 | |
| Graham Net | 0.58 | 10.94 | 8.47 | 6.07 | 0 | |
| Working capital | 50.24M | 44.23M | 36.66M | 30.5M | 19.72M | |
| Tangible asset value | 52.23M | 43.77M | 35.57M | 28.06M | 15.84M | |
| Net current asset value | 41.22M | 31.67M | 24.54M | 18.08M | 6.89M | |
| Invested capital | 0.17 | 0.29 | 0.35 | 0.45 | 0.82 | |
| Average receivables | 874K | 1.16M | 1.52M | 1.66M | 2.1M | |
| Average payables | 1.42M | 1.28M | 1.31M | 1.14M | 1.49M | |
| Average inventory | 1.54M | 1.44M | 1.33M | 1.28M | 1.19M | |
| Days sales outstanding | 107.88 | 207.92 | 180.18 | 164.69 | 155.11 | |
| Days payables outstanding | 616.62 | 745.36 | 848.33 | 323.87 | 756.86 | |
| Days of inventory on hand | 636.27 | 926.37 | 721.38 | 525.72 | 376.54 | |
| Receivables turnover | 0.83 | 0.43 | 0.5 | 0.55 | 0.58 | |
| Payables turnover | 0.15 | 0.12 | 0.11 | 0.28 | 0.12 | |
| Inventory turnover | 0.14 | 0.1 | 0.12 | 0.17 | 0.24 | |
| ROE | -0.12 | -0.32 | -0.27 | -0.35 | -0.87 | |
| Capex per share | 0 | 0 | -0.02 | 0 | 0 |
NVCN.TO Frequently Asked Questions
What is Neovasc Inc. stock symbol ?
Neovasc Inc. is a CA stock , located in Richmond of Bc and trading under the symbol NVCN.TO
What is Neovasc Inc. stock quote today ?
Neovasc Inc. stock price is $- today.
Is Neovasc Inc. stock public?
Yes, Neovasc Inc. is a publicly traded company.
Company Profile
- Volume Average 891
- Market Capitalization 110.78M
- Employee 49
- CEO Mr. Fredericus A. Colen
- Headquarters Richmond,BC,CA
- IPO Date 2014-06-23
-
Website
https://www.neovasc.com 
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
